Top Page
Karyopharm Therapeutics
(NASDAQ:KPTI)
Karyopharm Therapeutics (KPTI) vs. SPDR S&P 500 ETF (SPY)
Karyopharm Therapeutics Business Overview & Revenue Model
Karyopharm Therapeutics Earnings Call Summary
Karyopharm Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 142.53M | 145.24M | 146.03M | 157.07M | 209.82M | 108.08M |
| Gross Profit | 136.73M | 139.23M | 141.09M | 151.86M | 206.42M | 105.38M |
| EBITDA | -73.01M | -38.60M | -118.42M | -139.31M | -96.98M | -167.85M |
| Net Income | -124.62M | -76.42M | -143.10M | -165.29M | -124.09M | -196.27M |
Balance Sheet | ||||||
| Total Assets | 96.23M | 164.42M | 240.44M | 358.17M | 305.31M | 313.05M |
| Cash, Cash Equivalents and Short-Term Investments | 45.88M | 108.71M | 191.44M | 277.97M | 228.62M | 249.24M |
| Total Debt | 196.42M | 194.52M | 177.02M | 179.07M | 180.58M | 131.13M |
| Total Liabilities | 365.49M | 350.44M | 376.64M | 374.83M | 384.98M | 262.50M |
| Stockholders Equity | -269.26M | -186.02M | -136.21M | -16.66M | -79.67M | 50.55M |
Cash Flow | ||||||
| Free Cash Flow | -83.44M | -127.63M | -92.72M | -149.67M | -112.83M | -160.38M |
| Operating Cash Flow | -83.49M | -127.49M | -92.72M | -149.55M | -107.12M | -160.23M |
| Investing Cash Flow | 48.37M | 95.47M | 7.94M | -104.26M | 141.84M | -53.69M |
| Financing Cash Flow | 1.04M | 41.65M | 1.12M | 193.74M | 73.65M | 172.08M |
Karyopharm Therapeutics Technical Analysis
Karyopharm Therapeutics Risk Analysis
Karyopharm Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $48.36M | ― | -10.78% | ― | 5489.03% | 86.23% | |
45 Neutral | $89.01M | -0.35 | ― | ― | -3.98% | -29.94% | |
45 Neutral | $39.20M | -2.03 | -88.59% | ― | ― | -8.47% | |
41 Neutral | $42.11M | -1.03 | -130.59% | ― | -100.00% | 13.14% | |
37 Underperform | $36.54M | -0.15 | ― | ― | -63.88% | 77.72% | |
35 Underperform | $47.08M | ― | -340.46% | ― | ― | 4.01% |
Karyopharm Therapeutics Corporate Events
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing novel cancer therapies, particularly through its lead compound, XPOVIO (selinexor), which is approved for multiple oncology indications. The company operates in the biotechnology sector and is known for its pioneering work in nuclear export dysregulation.
On October 10, 2025, Karyopharm Therapeutics Inc. completed a series of financing transactions, including the issuance of convertible senior notes due in 2028 and 2029, and borrowed $12.5 million under its credit agreement. These transactions are aimed at strengthening the company’s financial position and supporting its strategic initiatives, potentially impacting its market standing and investor relations.
The most recent analyst rating on (KPTI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.
On October 7, 2025, Karyopharm Therapeutics announced a series of strategic financing transactions designed to provide $100 million in financial flexibility and additional capital, extending its cash runway into the second quarter of 2026. These transactions include new term loan borrowings, convertible notes, and a private placement of common stock, aimed at supporting ongoing and planned clinical trials. The company expects to generate approximately $36 million in cash proceeds from these transactions, which are set to close around October 10, 2025. This move is anticipated to strengthen Karyopharm’s balance sheet, equitize near-term debt maturities, and support its Phase 3 myelofibrosis program, potentially redefining treatment standards for the condition.
The most recent analyst rating on (KPTI) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.
Study Overview: The study titled A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) aimed to evaluate the efficacy and safety of selinexor combinations in treating RR DLBCL. This study was significant as it explored new therapeutic combinations for a challenging lymphoma subtype.
On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors of Karyopharm Therapeutics Inc., announced his resignation effective September 8, 2025, due to competing professional demands. Dr. Mirza’s resignation is not related to any disagreements with the company, and he is also stepping down from his role as Chief Oncologist at Copenhagen University National Medical Center to pursue a new executive role in the industry. Consequently, the consulting agreement between Karyopharm and Mirza Consulting was terminated as of September 8, 2025.
The most recent analyst rating on (KPTI) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.
Karyopharm Therapeutics Faces Mixed Fortunes Amid Clinical Success and Financial Strain
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing innovative cancer therapies, particularly through its pioneering work in nuclear export inhibition. In its latest earnings report for the second quarter of 2025, Karyopharm reported total revenue of $37.9 million, with U.S. net product revenue for its lead drug, XPOVIO, reaching $29.7 million, marking a 6% increase from the previous year. The company is on the brink of completing patient enrollment for its Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026.